683 Capital Management LLC Makes New Investment in Immuneering Corporation $IMRX

683 Capital Management LLC bought a new position in Immuneering Corporation (NASDAQ:IMRX) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 150,697 shares of the company’s stock, valued at approximately $992,000. 683 Capital Management LLC owned approximately 0.23% of Immuneering as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Immuneering by 10.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company’s stock worth $13,121,000 after purchasing an additional 195,176 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Immuneering in the 4th quarter worth $607,000. OMERS ADMINISTRATION Corp bought a new position in shares of Immuneering in the 4th quarter worth $315,000. Landscape Capital Management L.L.C. bought a new position in shares of Immuneering in the 4th quarter worth $542,000. Finally, Barclays PLC lifted its holdings in shares of Immuneering by 943.2% in the 4th quarter. Barclays PLC now owns 230,726 shares of the company’s stock worth $1,518,000 after purchasing an additional 208,608 shares in the last quarter. 67.65% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IMRX. Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Immuneering in a report on Tuesday, May 19th. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research note on Monday, March 9th. Oppenheimer restated an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Immuneering presently has an average rating of “Moderate Buy” and an average price target of $16.50.

Immuneering Price Performance

Shares of Immuneering stock opened at $4.41 on Thursday. Immuneering Corporation has a 1 year low of $2.06 and a 1 year high of $10.08. The firm has a market cap of $285.33 million, a PE ratio of -3.77 and a beta of 0.38. The stock has a fifty day moving average price of $5.09 and a 200-day moving average price of $5.34.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.09. As a group, equities analysts anticipate that Immuneering Corporation will post -1.12 EPS for the current fiscal year.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.